{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:08:49Z","timestamp":1767982129419,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several studies investigated diclofenac tissue concentrations using microdialysis (MD). However, thorough evaluations of the optimal MD set\u2010up for diclofenac are unavailable. Thus, this in vitro MD study aimed to compare different set\u2010ups to improve quantitative recovery of diclofenac. In forward and reverse in vitro MD experiments with diclofenac at two concentrations (1 and 100\u2009ng\/ml), the perfusion solutions physiological saline 0.9% (PS) and human albumin 1% (HSA) were compared using tissue probes (10\u2010mm membrane) and customized intravenous (iv) probes (30\u2010mm membrane). Using PS, the mean relative recovery of diclofenac at 1\u00a0ng\/ml was 1.6%\u2009\u00b1\u20090.04% and 3.12%\u2009\u00b1\u20090.00% with the tissue probe and the iv probe, respectively. The respective mean relative recovery for diclofenac at 100\u2009ng\/ml was 0.02%\u2009\u00b1\u20090.01% and 0.21%\u2009\u00b1\u20090.11%. Using HSA, the mean relative recovery was 314%\u2009\u00b1\u200925% (tissue probe) and 1064%\u2009\u00b1\u200997% (iv probe) for diclofenac at 1\u00a0ng\/ml and 444%\u2009\u00b1\u200991% and 1415%\u2009\u00b1\u2009217% for diclofenac at 100\u2009ng\/ml. In reverse dialysis using PS, the mean relative loss of diclofenac was 99.2%\u2009\u00b1\u20090.5% (tissue probe) and 95.8%\u2009\u00b1\u20091.7% (iv probe). Using HSA, the mean relative loss was \u22124.4%\u2009\u00b1\u20097.2% and 0.2%\u2009\u00b1\u20097.5%, respectively. PS and HSA were not suitable perfusion solutions for quantification of absolute diclofenac concentrations. Despite methodological challenges, HSA may be used for comparative experiments or bioequivalence studies.<\/jats:p>","DOI":"10.1111\/bcpt.13709","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T03:06:07Z","timestamp":1642647967000},"page":"468-480","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diclofenac in vitro microdialysis study comparing different experimental set\u2010ups to improve quantitative recovery"],"prefix":"10.1111","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-5878","authenticated-orcid":false,"given":"Anselm","family":"Jorda","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology Medical University of Vienna  Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Armogida","sequence":"additional","affiliation":[{"name":"Clinical Development GlaxoSmithKline Consumer Healthcare SARL  Nyon Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Lackner","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Medical University of Vienna  Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivasankari","family":"Saikumar","sequence":"additional","affiliation":[{"name":"Clinical Development GlaxoSmithKline Consumer Pvt Ltd  Hyderabad India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Sucharski","sequence":"additional","affiliation":[{"name":"Clinical Development GlaxoSmithKline Consumer Healthcare SARL  Nyon Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Medical University of Vienna  Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Medical University of Vienna  Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007400.pub3"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1352497"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X242584"},{"issue":"7","key":"e_1_2_9_5_1","first-page":"1092","article-title":"The percutaneous absorption of diclofenac","volume":"36","author":"Riess W","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2005.02484.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010015\u20101909\u20109"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000314698"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009\u20109236(97)90032\u20101"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1025719827072"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010017\u20100108\u20102"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13492"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcm.2016.02.012"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/011542650802300176"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.016"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035\u2010016\u20109929\u20108"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2012.06.010"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12125"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rinphs.2011.11.001"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2011.03914.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.5414\/cpp42353"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009\u20109236(03)00165\u20106"},{"issue":"9","key":"e_1_2_9_23_1","first-page":"1833","article-title":"Transdermal penetration of diclofenac after multiple epicutaneous administration","volume":"25","author":"M\u00fcller M","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2000.93.1.0037"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024\u20103205(88)90063\u2010x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471142301.ns0701s00"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702518"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s000110050329"},{"key":"e_1_2_9_29_1","unstructured":"European Medicines Agency.Draft guideline on quality and equivalence of topical products.2018."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0169\u2010409x(00)00108\u20103"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1549\u20108719.2010.00077.x"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/41.10.1522"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2005.01.017"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13709","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.13709","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T18:38:06Z","timestamp":1692729486000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/bcpt.13709"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13709","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"2021-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}